Evidence that remdesivir treatment reduces viral titers in patients with COVID-19

Simon Boyd; Shivani Singh; William HK Schilling; Sir Nicholas White

doi:10.1128/aac.01266-24

Related publications

Article2020

Remdesivir for COVID-19 in Europe: will it provide value for money?

Rafael Dal‐Ré, Rita Banzi, Sophie Georgin‐Lavialle, Raphaël Porcher, Reecha Sofat, Markus Zeitlinger, Frits R. Rosendaal

The Lancet Respiratory Medicine

Article2021

COVID-19 ziekenhuisopnames in context

Bob Siegerink, Frits R. Rosendaal, Dennis O. Mook‐Kanamori

Article2004

Fluvastatin Reduces Cardiac Mortality in Patients with Coronary Heart Disease

Christie M. Ballantyne, Günter A.J. Riegger, Nicholas Moore, Francesco Saia, Patrick W. Serruys

Cardiovascular Drugs and Therapy

Article2021

A MULTICENTRIC STUDY TO ASSESS THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH SLE IN INDIA

Manish Kumar Goyal, Prabhavati Patil, Harsh Pathak, Sham Santhanam, Aimee Goel, Vijay Kumar Sharma, Ankita Pandey, Nikhil Gupta, Rahul Kumar Jain, Shashank Akerkar, Pranta Das, Rajkiran Dudam, Naval Mendiratta, B. D. Pandey, CB Mithun, B. K. Singh, S. Dinesh Kumar, Nilesh Nolkha, Seema Jain, Anu Sharma, Deepankar Misra

Internal Medicine Journal

Article2024

TCT-676 Incidence of Coronary Microvascular Dysfunction in ANOCA Patients With and Without a History of Severe Covid-19 Infection: The COMET-19 Study

TsungYing Tsai, Ali Aldujeli, Ayman Haq, Kasparas Briedis, Diarmaid Hughes, Ramūnas Unikas, Mick Renkens, Kotaro Miyashita, Akihiro Tobe, Asahi Oshima, Faisal Sharif, Scot Garg, Yoshinobu Onuma, Emmanouil S. Brilakis, Patrick W. Serruys

Journal of the American College of Cardiology